Home » Newsletters » BioWorld Science

BioWorld Science

April 6, 1998

View Archived Issues

Axcan: Annual Report 1997

ART-123, a human recombinant thrombomodulin, demonstrates acceptable safety profile

Novel HIV vaccine available for licensing from NIH

Green Cross reveals potent, selective angiotensin II antagonists

Agents for hyperlipidemia under investigation at HMR

TER-199 resistance-modulating mechanisms explored

Inhale reports successful phase I and II results with drugs from Baxter collaboration

Vaxcel acquires rights to cancer antigen

Amidino derivatives for thrombosis reported by Astra

Protein tyrosine kinase inhibitors emerge from R&D at Glaxo Wellcome

Takeda claims bicyclic compounds for micturition disorders

American Home Products synthesizes and evaluates new smooth muscle relaxants

Highly potent GH secretatogues discovered by Merck & Co.

Selective PDE IV/TNF-alpha inhibitors focus of research at Yamanouchi

Pivotal phase III trial of Nabi-StaphVAX now under way

New U.S. patent provides further protection for Onconase and related products

Orally active thrombin inhibitor discovered at Pfizer shows good tolerance in phase I

The alpha1L-adrenoceptor: a new target for BPH therapy

Norian and Shofu collaborate on new applications for Norian SRS

RS-100975, a prostate-selective alpha-blocker in vitro

Prostate cancer immunotherapeutic evaluated in preclinical and clinical trials

Leukocyte activation inhibitor active in animal models of myocardial infarction

EchoGen recommended for approval in the European Union

Antiplatelet and antithrombotic effects of FR-171113 in guinea pigs

Baxter suspends study of HemAssist in U.S. trauma patients; other trials continue

Genetronics' EPT plus bleomycin looks effective in prostate cancer

YM-905 shows promise as safe and effective treatment for overactive detrusor

YM-905 shows promising activity in animal model of IBS